ATNM Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -380280%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Altimmune, Inc.'s return on equity of -56.24%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 290.63%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 320.12%. Given that Altimmune, Inc. has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Actinium Pharmaceuticals, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.258% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are larger than Altimmune, Inc. quarterly revenues of $5K. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 443.68x versus 16,778.75x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Assertio Holdings, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of 23.14%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Assertio Holdings, Inc.'s return on equity of -25.86%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 290.63%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 241.64%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Assertio Holdings, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.258% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.519%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Assertio Holdings, Inc. quarterly revenues of $49.5M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 443.68x versus 4.36x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Avanos Medical, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -0.79%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Avanos Medical, Inc.'s return on equity of -52.63%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 290.63%. On the other hand Avanos Medical, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 13.36%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Avanos Medical, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.258% less volatile than S&P 500. In comparison Avanos Medical, Inc. has a beta of 1.079, suggesting its more volatile than the S&P 500 by 7.932%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avanos Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Avanos Medical, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Avanos Medical, Inc. quarterly revenues of $177.8M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than Avanos Medical, Inc.'s net income of -$1.4M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Avanos Medical, Inc.'s PE ratio is 45.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 443.68x versus 0.82x for Avanos Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -255.85%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 290.63%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -94.25%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.258% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 24.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 443.68x versus 28.70x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.